The country will invest more than 100 billion yuan to support the creation of major new drugs

The biomedical promotion plan is about to be unveiled.

A person from the Pharmaceutical Industry Association stated that the plan has been submitted to the National Development and Reform Commission.

Another expert who participated in the National Twelfth Five-Year Plan for the implementation of a major new drug creation project revealed that the country will spend more than 10 billion yuan to support the creation of major new drugs, with an average of 5 to 10 million yuan for each new drug project. funds.

As the key supporter of this time, the country has selected more than 10 original innovative drugs from more than 100 new drugs, which may become a pioneer in the European and American markets. This involves more than 10 companies and research institutes including Hengrui Pharmaceutical, Shanghai Pharmaceutical Group, North China Pharmaceutical, and Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Revitalization plan is about to come soon

The biomedical promotion plan was led by the National Development and Reform Commission, and was jointly formulated by the Ministry of Science and Technology, the Ministry of Health, and the State Food and Drug Administration. After many arguments and revisions, it was finalized.

According to a person in charge of the pharmaceutical industry, “the process is being followed, but the word “revitalization plan” is not used, it is called the “12th five-year” development plan for biomedicine.”

Although the national level revitalization plan has not yet been introduced, it has been in full swing. The governments of Jiangsu, Shanghai, Beijing, and Sichuan have incorporated biomedicine into the emerging industry revitalization plan that is being implemented.

Among them, Sichuan has listed biopharmaceuticals as one of the emerging industries for Sichuan's "Twelfth Five-Year Plan" sprint. Jiangsu hopes that by 2012, sales of biopharmaceuticals will exceed 500 billion yuan. At present, the annual output value of biopharmaceutical industry in Jiangsu is about 200 billion yuan, accounting for 11.5% of the country's total.

Beijing strives to increase the scale of the biomedical industry from less than 40 billion yuan to 100 billion yuan in the next three years. Shanghai plans to bring the total economic value of the biomedical industry to 200 billion yuan by the end of 2012.

The "12th Five-Year Plan" of biomedicine has identified the priorities for the development of biomedicine, including genetic drugs, protein drugs, monoclonal antibody cloning drugs, therapeutic vaccines, and small molecule chemical drugs.

Supporting research and development of special funds <br> <br> the same time, developed by the Ministry of Science, the Ministry of Health and other "significant Drug Discovery" science and technology major projects, "five-second" Implementation Plan (2011- biomedical "five-second" industrial planning 2015) is also under development.

The Ministry of Health pointed out that the “Twelfth Five-Year Plan” still has “Innovative Drug Research and Development”, “Technical Transformation of Major Drug Varieties”, “Innovation Drug Research and Development Technology Platform Construction”, “Innovation Drug Incubation Base Construction” and “New Drug Research and Development” Key technology research "5 items.

In the "innovative drug research and development", according to different categories of chemical drugs, Chinese medicine and biological medicine, the state gives different financial support. Among them, the funding for each research project for clinical research on innovative drugs ranges from 500 to 11 million yuan; the funding for each pre-clinical research project ranges from 300 to 5 million yuan; and the funding for new clinical trials on foreign trials covers 15 to 25 million per project. Yuan, commitment unit investment is not less than 1:4.

The above-mentioned experts participating in the "Creation of Major New Drugs" project disclosed that, for individual new drug R&D projects, the average amount of support funds provided by the state is between 5 million and 10 million yuan; R&D platforms can be supported by hundreds of millions or even tens of millions of yuan. "The Chinese Academy of Sciences The Shanghai Institute of Materia Medica received 200 million yuan of state project funding support."

According to the person in charge of the industry association, “The state is selecting more than 10 more mature varieties from more than 100 original innovative medicines as the key support targets. During the 12th Five-Year Plan period, it is likely that it will be approved for listing.” And in these varieties Among them, biological drugs and chemical drugs are mostly.